ANTIBODY DRUG CONJUGATE SUMMIT

 - 

ANTIBODY DRUG CONJUGATE SUMMIT

This innovative B2B event will enable the participants to learn about protein modeling development and engineering advances, preclinical and clinical improvements, current ADC linker chemistry- better linker design for future generations, improving preclinical and clinical translation and creating strong and scalable processes.

 

It is an honour and privilege to invite you to participate in this Summit. We look forward to welcoming you in Lisbon!

Key Practical Learning Points of the Summit:

  • Increase benefits of ADC- dial in potency, target stratified patient populations and optimize dosing regimens
  • Ensure product and process robustness Make more evidence-based decisions
  • Explore alternative opportunities for ADCs by reviewing the potential of using ADCs outside oncology Learn about advances in Protein Modeling and Engineering Breakthroughs
  • How to screen for optimal site of conjugation, select better quality targets and explore new payload mechanisms of action

 

Who Should attend:

CEOs, Directors, Heads & Managers Of Leading Application Creators & Suppliers 

 

From Industries Including:

  • Pharmaceuticals
  • Biologics
  • Medicine 
  • Clinical Research Organizations

 


Building:not final
Address:not final
CountryPortugal
Type:Conference
Return to overview